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Abstract
Background: Despite recent progress, investigating the impact of targeted therapies on Head and Neck Squamous
Cell Carcinoma (HNSCC) remains a challenge. We investigated whether short-term culture of tumour fragments
would permit the evaluation of tumour sensitivity to targeted therapies at the individual level.
Methods: We cultivated tumour slices prepared from 18 HNSCC tumour samples obtained during surgical
resection. The samples were treated for 48 h with a panel of 8 targeted therapies directed against selected
oncogenic transduction pathways. We analysed the cell proliferation index (CPI) of tumour cells using Ki67 labelling
and the activation status of the RAF-MEK-ERK cascade through ERK phosphorylation analysis.
Results: Fourteen tumours were successfully analysed after short-term culture of tumour samples, revealing a
striking individual heterogeneity of HNSCC in terms of tumour cell sensitivity to targeted therapies. Using 50 %
inhibition of CPI as threshold, sorafenib was shown to be active in 5/14 tumours. Cetuximab, the only approved
targeted drug against HNSCC, was active in only 2/14 tumours. A more than 50 % inhibition was observed with at
least one drug out of the eight tested in 10/14 tumours. Cluster analysis was carried out in order to examine the
effect of the drugs on cell proliferation and the RAF-MEK-ERK cascade.
Conclusions: In vitro culture of tumour fragments allows for the evaluation of the effects of targeted therapies on
freshly resected human tumours, and might be of value as a possible guide for the design of clinical trials and for
the personalization of the medical treatment of HNSCC.
Keywords: Head and neck squamous cell carcinoma, Short-term culture of tumour fragments, Targeted therapies,
Treatment personalization
Background
Head and neck squamous cell carcinomas (HNSCC) are
tumours characterized by great phenotypic, aetiological
and biological heterogeneity among individuals [1]. Stand-
ard options for locally advanced HNSCC are surgery and
adjuvant radiotherapy or cisplatin-based chemoradiother-
apy, depending on associated risk factors [2]. Chemoradio-
therapy is used alone for non-resectable tumours [2].
However, a large number of patients display locoregional
and/or metastatic recurrence despite an adequate local
treatment. Cetuximab, a monoclonal antibody directed
against the Epidermal Growth Factor Receptor (EGFR), is
the only targeted therapy approved for advanced HSNCC.
It is used in combination with radiotherapy for locally ad-
vanced disease [3] or with platinum-based chemotherapy
for palliative purposes [4, 5]. Epidermal Growth Factor
(EGFR) is almost systematically overexpressed in HNSCC,
but no clear correlation has been established between
EGFR expression levels and individual response to cetuxi-
mab [6]. Primary resistance to cetuximab is estimated to
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occur with a frequency of 13–35 % [4, 5]. Acquired resist-
ance also appears more or less rapidly during the treat-
ment, through mechanisms that are complex and to date
only partially understood [7].
While every individual HNSCC bears a unique load of
genomic alterations, therapeutic targeting is limited by
the fact that the current level of genomic analysis does
not translate into clear information regarding tumour
sensitivity to most drugs [8]. New companion assays that
would help to predict individual tumour sensitivity to
cetuximab and other treatments of HNSCC would be of
medical and economic interest. Such companion assays
would help to personalize the medical treatment of pa-
tients with HNSCC, and would also be helpful for the
optimization of phase II and III clinical trials of new tar-
geted therapies. We and others have examined the possi-
bility of cultivating fragments of human solid tumours
for a short-period of time, and exposing them to tar-
geted therapies in vitro [9–13]. Two preliminary studies
in particular provide a proof of principle that short-term
culture is applicable for exploring the heterogeneity of
individual responses of HNSCC to cetuximab [12, 13].
In the present study, we prepared tumour slices from




This study was conducted in compliance with the
French legislation and the declaration of Helsinki re-
garding ethical principles for medical research involving
human subjects. The use of surgically-resected solid tu-
mours for research purposes in the laboratory of Bio-
chemistry of the University Hospital of Amiens was
approved by the Comité de Protection des Personnes
Nord-Ouest (CPP NO ref. 2009/14). A written consent
was obtained from the patients. No samples were ob-
tained from any patients that were minor or physically
or mentally unable to understand and give their consent
to the use of surgical samples.
Head and neck tumour specimens were obtained from
18 adult patients who had been referred to the Head and
Neck department of Amiens University Hospital (France)
for a surgical procedure between September 2013 and
September 2014. Surgery was the first line of treatment,
without previous radiotherapy or chemotherapy. Different
localisations and stages of squamous cell carcinoma from
the upper aero-digestive tract are represented (Additional
file 1: Table S1) [14].
Preparation of tumour slices and culture
About 1 cubic cm of non-necrotic tumour was selected
by the pathologist from each fresh surgical specimen.
Tumour samples were prepared as 300 μm thick slices
with a vibrating blade microtome (VT1200S Vibratome,
Leica). Slices were maintained for 48 h in 24-well culture
plates in Dulbecco’s Modified Eagle Medium (DMEM)
culture medium, supplemented with 10 % fetal calf
serum (PAN-Biotech), penicillin / streptomycin, and 1 %
glutamine at 37 °C in a 5 % CO2 atmosphere.
Drugs
Eight targeted therapies (cetuximab, sorafenib, erlotinib,
tivaninib, masitinib, ponatinib, afatinib and rapamycin)
were selected on the basis of their distinct reactivities to-
ward oncogenic kinases (Table 1). Drug concentrations
applied in the culture medium were chosen from previ-
ous pharmacological studies [7, 15–18]. Cetuximab was
purchased from Merck-Serono. Sorafenib, erlotinib, tiva-
ninib, masi tinib, ponatinib, afatinib were purchased by
Euromedex (Souffelweyersheim, France). Rapamycin was
purchased from Sigma (Sigma-Aldrich, France). Except
for cetuximab, which was kept in saline, all other drugs
were dissolved in DMSO and kept at – 20 °C before use.
Immunohistochemistry
Tumour slices were fixed in formalin and then paraffin-
embedded; 3 μm sections were cut and stained with
hematoxylin phloxin saffron (HPS) to select non-
necrotic and non-fibrotic areas with a high density of
tumour cells. The monoclonal antibody MIB1 (Immuno-
tech, Marseille, France) was used for the immunostain-
ing of Ki67. Two tumour slides were analyzed for each
experimental condition. Ten microscopic pictures were
taken from each slide focusing on non-necrotic and
non-fibrotic tumour areas, as defined by a senior path-
ologist (J.-F.I.). The cell proliferation index (CPI) was
calculated from tumour cells only, excluding cells from
the matrix and vessels. The ratio of Ki67-positive cells
(brown stained nuclei / total number of nuclei × 100)
was automatically determined by using ImmunoRatio,
an Image J plugin adapted to automated image analysis
(http://jvsmicroscope.uta.fi/sites/default/files/software/
immunoratio-plugin/index.html). The total number of
pictures analyzed was 20 per experimental condition,
representing in total a minimum of 1000 tumour cells.
Mean CPI was determined by calculating each time the
average, using the results from all slides.
Immunoblots
Tumour slices treated as indicated were kept at −20 °C
for immunoblotting. Total extracts were prepared as de-
scribed previously and loaded on polyacrylamide gels
(SDS-PAGE) and transferred to nitrocellulose mem-
branes [11]. Antibodies against Extracellular Regulated
Kinase 1/2 (ERK) and phosphorylated ERK1/2 (pERK)
were from Cell Signaling Technology (Danver, MA,
USA). Antibodies against β actin were from Sigma (Saint-
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Quentin Fallavier France). Secondary antibodies coupled
to peroxydase were from GE Healthcare (Aulnay-
sous-Bois, France). Enhanced chemiluminescence re-
action was used for revelation. Immunoblots were
scanned and quantified using the software Image J
(National Institute of Health, USA).
Statistical analysis
The Student’s t-test was used for individual biological ana-
lysis and a value of p < 0.05 was considered as threshold
for significance. Pearson’s r test was used for correlation
analysis. Hierarchical cluster analysis was performed with
the software R3.02 (http://www.r-project.org/). The hclust
function in R was used, using the agglomeration method
“complete”. The algorithm proceeds iteratively. At each
stage distances between clusters are recomputed by the
Lance–Williams dissimilarity update formula.
Results
Short-term culture of tumour samples for the analysis of
the effects of targeted therapies on individual HNSCC
tumours
In order to analyse the impact of targeted therapies
against HNSCC, we designed a panel consisting of
eight targeted therapies that have reached at least
phase II/III in clinical trials for the treatment of vari-
ous solid tumours. This panel included the drugs
cetuximab, sorafenib, erlotinib, tivaninib, masitinib,
ponatinib, afatinib and rapamycin, and was selected
on the basis of the distinct reactivities of these com-
pounds against important oncogenic kinases (Table 1).
Tumour samples were obtained from 18 patients ad-
dressed for surgical resection of HNSCC (Additional file 1:
Table S1). Tumour slices were prepared from each tumour,
and maintained for 48 h in culture with each anti-cancer
drug applied at pharmacological concentrations. This time
point was selected on the basis of our previous study
showing a good preservation of cell viability and tumour
architecture in these conditions [13]. Four out of the 18
tumour samples were not exploitable after 48 h of culture
because there were not enough identifiable tumour cells
identifiable at the time of histological examination. The
reason for this failure to maintain these four tumours suc-
cessfully in culture is not clear at this stage. Some possible
explanations may include low tumour cellularity, pre-
existence of necrotic areas, culture-induced necrosis, or a
simultaneous occurrence of these.
We focused our analysis on the 14 other tumour
samples. The effect of each treatment was analysed by
exploring the % of tumour cells labelled with Ki67 by
immunohistochemistry (Fig. 1). We found that the
effect of treatment on cell proliferation greatly varied
depending on the drug and the patient (Fig. 2). When
we set the cut off for CPI inhibition induced by each
drug in comparison to control at 50 %, cetuximab
was shown to be active against two out of fourteen
tumours. In some cases, the targeted therapy was
shown to increase cell proliferation in comparison to
control (i.e., rapamycin or tivantinib, in one tumour
each). Sorafenib was the drug that was active in the
largest proportion of tumours (5/14). Interestingly,
ponatinib and masatinib were also active on some
HNSCC tumours (3/14). In total, a more than 50 %
CPI inhibition was observed in 10/14 tumours for at
least one drug.
Comparing the anti-proliferative efficacies of various
therapeutic drugs using short-term culture of tumour
slices
In order to explore the efficacy of each drug at the
level of the entire tumour population, we performed a
dendrogram analysis of the measurements obtained in
the proliferation assays. The cluster analysis was per-
formed using the values measured with Ki67 labelling
(Fig. 3). However, compared to the data presented
earlier, normalization step was introduced, with con-
trol condition taken as reference for the calculation
of the % inhibition of Ki67-labelling by each drug.
Table 1 A summary of the drugs used in this study and their inhibitory spectrum against the cellular kinome
Name Concentration used Main kinase target Reference
Cetuximab 30 μM EGFR (Epidermal Growth Factor Receptor) [7]
Erlotinib 1 μM EGFR [15]
Afatinib 10 μM EGFR / ErbB2/ ErbB4 [15]
Sorafenib 10 μM B-RAF, C-RAF, PDGFR-A, PDGFR-B (Platelet-Derived Growth Factor Receptor) [15]
VEGFR-2 (Vascular Endothelial Growth Factor-2)
Masitinib 10 μM KIT, PDGFR-A, PDGFR-B [15]
Tivantinib 10 μM HGFR (Hepatocyte Growth Factor Receptor) [16]
Ponatinib 1 μM FGFR1-4 (Fibroblast-Growth Factor Receptor), PDGFR-A, VEGFR-2 [17]
Rapamycin 1 μM mTOR (mammalian Target Of Rapamycin) [18]
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This normalization step was applied in order to minimize
the impact of heterogeneous proliferative index in individ-
ual tumours and therefore facilitate the comparison of the
effects of drugs. Interestingly, the subsequent cluster ana-
lysis revealed that some drugs displayed a shared pattern
of efficacy with others (Fig. 3). The three drugs that were
initially selected on the basis of their reactivity toward the
EGFR-RAF-MEK-ERK pathway, i.e., cetuximab, erlotinib
and sorafenib, displayed neighbouring activity in terms of
effect on tumour cell proliferation in HNSCC. Interest-
ingly, afatinib, another compound presumed to inhibit
EGFR, did not cluster with cetuximab, erlotinib and soraf-
enib (Fig. 3). These findings suggest that afatinib did not
exert its control over HNSCC tumour proliferation
through the same mechanisms as the other three drugs.
Exploring the impact of targeted therapies on the
RAF-MEK-ERK cascade in individual tumours using
short-term culture of tumour slices
In order to further explore the use of short-term cul-
ture of tumour fragments, an immunoblot analysis of
the expression levels of the markers ERK and
phospho-ERK (pERK) was performed on samples ob-
tained in the same conditions as previously (Fig. 4).
The levels of ERK phosphorylation, reflecting the acti-
vation of the RAF-MEK-ERK cascade, were analysed
in 10 tumours for which sufficient tumour material
was available. A representative immunoblot is shown
in Fig. 4a. For all samples, a ratio of pERK/ERK was
calculated after densitometric analysis of the immuno-
blot. This ratio was used for dendrogram analysis (Fig. 4b).
Fig. 1 Representative microscopic acquisitions showing tumour cell proliferation assessed by Ki67 staining. Pictures are from tumour slices
obtained from four different patients and analysed after 48 h of culture. Tumour slices were maintained in control conditions (a, c) or exposed to
cetuximab (b, d). Ki67 immunostaining is shown in panels a and b. Automatic identification of stained nuclei is shown in panels c and d. The
nuclei that are recognized as negative for Ki67-labelling are shown in blue, while those identified as positively stained are shown in orange. The
four examples shown are representative of tumour areas with different proportions of proliferating cells, as defined by the % of Ki67 labelling
(X 40 in a, b; X4 in c, d)
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Interestingly, cetuximab, erlotinib and sorafenib displayed
neighbouring activity on the phosphorylation of ERK,
while afatinib did not cluster with these three drugs
(Fig. 4b). These findings were consistent with our previous
analysis, centred on cell proliferation, and confirmed the
relevance of the analysis of ERK phosphorylation in this
setting.
We further explored the possibility that the prolifera-
tion levels and pERK/ERK ratios might be linked by per-
forming a correlation analysis for each drug (Fig. 5).
Interestingly, a correlation was found between the con-
trol exerted over tumour cell proliferation and the RAF-
MEK-ERK cascade for erlotinib (r2 = 0.2018, p = 0.0277
using Pearson’s r test) (Fig. 5a). No such correlation was
found for tivantinib (r2 = 0.65 × 10−4, p = 0.9680) (Fig. 5b).
We concluded that short-term culture of tumour slices
is suitable for the exploration of the effects of thera-
peutic drugs on HNSCC.
Discussion
Here, we explored the individual sensitivity of
HNSCC tumours that were exposed in culture to
various drugs, using a procedure that has been de-
scribed by us and others and applied to a variety of
human solid tumours in the past [9–13]. The tumour
samples were sliced and maintained in culture for
48 h. This time point was chosen as a compromise,
in order to let the tumour cells undergo in theory
two proliferation cycles without inducing any massive
cell death due to the cell culture conditions [13].
Fig. 2 Effect of targeted therapies on the cell proliferation index in six representative HNSCC tumours in short-term culture. The histograms represent
the average % of tumour nuclei stained with Ki67. The average presented is based on the automatic quantification of 20 tumour fields from two slides,
representing a minimum of 1000 tumour cells for each condition, as indicated in the Materials and methods section. Each treatment was maintained
in culture for 48 h. Note that each individual tumour presents a different % of Ki67-positive cells in control conditions, reflecting individual differences
in the basal proliferative index. * indicates a statistically-significant difference compared to control conditions, corresponding to culture without
treatment, with p <0.05 (Student’s t-test)
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Following the identification of areas with high density
of tumour cells, Ki67 labeling combined with auto-
mated image analysis was applied in order to examine
the impact of a panel of targeted therapies on tumour
cell proliferation. We show that short-term culture is
a simple and robust method for the evaluation of the
effects of targeted therapies on fresh human tumours,
i.e., in conditions that resemble as closely as possible
the clinical setting.
We observed that proliferation was inhibited by at
least one drug in 10/14 HNSCC tumours in our experi-
mental conditions. At this stage however, the aim of the
present study was not to raise any definitive conclusions
regarding the sensitivity of HNSCC to each of the drugs
that was tested. Indeed, there are three major limitations
to this study: i) the first limitation is the fact that a single
pharmacological concentration of each drug was tested.
Future studies should ideally assess a range of concen-
trations to determine an optimal inhibitory concentra-
tion for each drug. ii) The second major limitation of
the use of tumour slices maintained ex vivo is that they
reflect the consequences of the direct inhibition of signal
transduction pathways inside tumour cells. Short-term
culture of tumour slices cannot be used to evaluate anti-
angiogenic or immunotherapeutic procedures, whose
effects on tumour cells are indirect and require mid- to
long-term exposure. ii) The third limitation of the
present study is the limited number of tumours analysed
(n = 14), which does not allow us to draw any definitive
conclusions regarding the frequency with which tumours
are resistant or sensitive to different drugs. Having in
mind these limitations, it is nevertheless interesting
to note that cetuximab, the only approved drug for
the treatment of HNSCC that was tested in the
panel, significantly inhibited the proliferation of only
two tumour samples. An anti-proliferative effect was
more often observed with sorafenib (n = 5), masitinib
(n = 3), and afatinib (n = 3), thus opening the possibil-
ity that some HNSCC tumours might be individually
sensitive to these drugs. At this stage, we conclude
that short-term culture of tumour samples is a tech-
nique that could be useful for exploring the tumour-
intrinsic determinants of drug sensitivity at the indi-
vidual level.
Fig. 3 Dendrogram analysis exploring the anti-proliferative effects of targeted therapies in HNSCC slices. The analysis was conducted in
the 14 HNSCC tumours, based on the calculated % inhibition of cell proliferation, i.e., based on the % of labelling of Ki67 in tumour cells,
after normalization. Control condition for each tumour sample was taken as reference (100 %) for the calculation of the % inhibition of
Ki67-labelling by each drug. This normalization step was applied in order to minimize the impact of the heterogeneous basal proliferative
index of individual tumours, and in order to preferentially address the effects of the different drugs. Following this normalization, a cluster
analysis was performed in order to identify drugs with neighbouring activities on Ki67 labelling. Bold and italic characters indicate
conditions with a greater than 50 % inhibition of proliferation. Empty cases indicate conditions where tumour material was not
sufficient for analysis
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Beyond this exploration of individual tumour sensitiv-
ity, cluster analysis that was built from the results of all
drugs on tumour cell proliferation resulted in a pattern
that was concordant with the known mechanisms of
some of the drugs. Cetuximab, erlotinib and sorafenib,
which are drugs that target the EGFR-RAF-MEK-ERK
transduction pathway, presented related patterns of anti-
proliferative efficacy. The observation validated the re-
sults of the assay, while providing another practical dem-
onstration of the interest of short-term culture of
tumour samples. Afatinib, whose mode of action is
thought to be the inhibition of EGFR, was found to ex-
hibit an activity spectrum distinct from those of the
others EGFR-RAF inhibitors. In agreement with these
observations, a correlation was established between the
extent of the inhibition of ERK phosphorylation and the
control of HNSCC proliferation with erlotinib, but not
with afatinib. Given the poor specificity of most inhibi-
tors of tyrosine kinase currently in clinical use, add-
itional mechanisms of action beyond EGFR inhibition
and the control of the EGFR-RAF axis can therefore be
hypothesized for a drug like afatinib [15]. On the basis
of these data, we suggest that short-term culture of
tumour samples can also be useful for addressing the
mode of action of anticancer drugs on HNSCC.
Compared to other techniques aimed at exploring the
sensitivity of individual solid tumours in general and
HNSCC in particular, the preparation of slices offers the
Fig. 4 ERK1/2 kinase phosphorylation analysis for the exploration of the mode of action of targeted therapies against HSNCC. a Immunoblot analysis
performed upon short-term culture of a representative HNSCC tumour. Sample fragments obtained from tumour #5 were processed and analysed by
immunoblotting for the indicated markers, with β-actin used as a loading control. b Dendrogram analysis based on the pERK / ERK ratio calculated for
each condition. For each condition, an immunoblot analysis was performed on one slice cultured as indicated. Normalization of pERK/ERK ratio was
applied in order to minimize the impact of the heterogeneity of individual tumours, by setting the value of the pERK/ERK ratio to 1 for control
conditions. Following this normalization, a cluster analysis was performed in order to identify drugs with neighbouring activities on ERK
phosphorylation. Bold and italic characters indicate conditions with a greater than 50 % inhibition of ERK phosphorylation
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advantage of being relatively easily performed and
rapidly implemented. It might be therefore suited for
rapid exploration of the response of a relatively-large
number of tumours exposed to anticancer drugs. In
theory, we propose that short-term culture of slices
might serve as a basis for new companion assays that
might be useful for the design of clinical trials testing
the efficacy of anti-cancer drugs [19]. Ultimately, it is
also tempting to propose that it could be used to se-
lect the most active targeted therapies for individual
patients with advanced HNSCC. More studies are
however required in order to establish the optimal
culture conditions, as well as the biochemical and
histological readouts that best reflect the efficacy of
anticancer drugs against HNSCC. Validation of the
short-term culture assay will require a comparison
with the results obtained with other, more established
models currently used for the determination of tumour
drug-sensitivity, such as patient-derived xenografts [18].
Finally, in the present study, we did not carry out a correl-
ation of the in vitro behaviour of tumour cells with the
clinical response, since most patients enrolled here were
considered cured after surgery and thus did not receive
any targeted therapy.
Conclusion
Short-term culture of tumour slices can be applied to
evaluate the effects of targeted therapies on freshly-
resected human HNSCC tumours. Future in vitro stud-
ies and clinical trials are required in order to: i) optimize
the conditions for the assessment of tumour sensitivity
in individual patients; ii) compare the results of the assay
with the clinical response of patients with advanced /
metastatic HNSCC. Together with other functional
assays that explore complex aspects of cancer cell physi-
ology, such as the functional state of the cell death
machinery [20] and genomic assays, short-term culture
of tumour fragments may offer new possibilities for the
optimisation of treatment for individual cancer patients.
Additional file
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